Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.

[1]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[2]  S. Russell,et al.  Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. , 2016, JACC. Heart failure.

[3]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[4]  John A. Galdo,et al.  Hypoglycemic agents and potential anti-inflammatory activity , 2016, Journal of inflammation research.

[5]  B. Okopień,et al.  Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner , 2016, Pharmacological reports : PR.

[6]  Lingling Wu,et al.  Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation. , 2015, Biochemical and biophysical research communications.

[7]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[8]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[9]  M. Yoshizumi,et al.  Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways , 2015, PloS one.

[10]  Y. Birnbaum,et al.  Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings , 2015, Cardiovascular Drugs and Therapy.

[11]  A. Scheen,et al.  Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. , 2015, Diabetes & metabolism.

[12]  Feng Bai,et al.  Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart , 2015, Cardiovascular Drugs and Therapy.

[13]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[14]  Y. Birnbaum,et al.  Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size: An Adenosine and Cyclooxygenase-2–Dependent Effect , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[15]  J. Mehta,et al.  GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A , 2014, Journal of cardiovascular pharmacology.

[16]  Y. Birnbaum,et al.  Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury , 2014, Journal of cardiovascular pharmacology and therapeutics.

[17]  D. Wootten,et al.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation , 2014, British journal of pharmacology.

[18]  J. Berger.  Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. , 2013, The American journal of cardiology.

[19]  P. Doevendans,et al.  Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. , 2013, International journal of cardiology.

[20]  A. Dear,et al.  The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model , 2013, Diabetes & vascular disease research.

[21]  E. Horton,et al.  Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. , 2013, Diabetes research and clinical practice.

[22]  J. Ayala,et al.  Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. , 2013, American journal of physiology. Cell physiology.

[23]  S. Yamagishi,et al.  Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. , 2013, The American journal of pathology.

[24]  Y. Birnbaum,et al.  Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. , 2012, Metabolic syndrome and related disorders.

[25]  S. Yamagishi,et al.  Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. , 2012, Microvascular research.

[26]  S. Nishikawa,et al.  Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes , 2012, Diabetes.

[27]  H. Yokomizo,et al.  GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. , 2012, Metabolism: clinical and experimental.

[28]  V. Allgar,et al.  A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure , 2012, International journal of peptides.

[29]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[30]  C. Terkelsen,et al.  Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia , 2012, Circulation. Cardiovascular interventions.

[31]  S. Yamagishi,et al.  Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. , 2011, Metabolism: clinical and experimental.

[32]  P. Hruz,et al.  Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy , 2011, PloS one.

[33]  S. Miyamoto,et al.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes , 2011, Diabetologia.

[34]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[35]  A. Dear,et al.  A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. , 2009, The Journal of endocrinology.

[36]  D. Yellon,et al.  GLP-1 therapy: beyond glucose control. , 2008, Circulation. Heart failure.

[37]  I. Poornima,et al.  Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat , 2008, Circulation. Heart failure.

[38]  B. Uretsky,et al.  Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. , 2007, American journal of physiology. Heart and circulatory physiology.

[39]  J. Lim,et al.  Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. , 2007, Journal of the American Society of Nephrology : JASN.

[40]  J. Perez-polo,et al.  Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. , 2007, Prostaglandins & other lipid mediators.

[41]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[42]  E. Braunwald,et al.  Use of composite endpoints in thrombolysis trials of acute myocardial infarction. , 1993, The American journal of cardiology.